Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 24, 2017
The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms
Gisela Kobelt, Jennifer Eriksson, Glenn Phillips, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 26, 2025
Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample
Sarah Dewilde, Mathieu F Janssen, Glenn Phillips, et al.
Archives of Public Health = Archives Belges De Sante Publique
|
July 11, 2025
POPUP: an observational digital study reporting general population norms for the EQ-5D-5-L and HUI-3 in 8 countries
Sarah Dewilde, Nafthali Hananja Tollenaar, Glenn Phillips, et al.
Advances in Therapy
|
March 3, 2023
Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities
Sarah Dewilde, Cynthia Z Qi, Glenn Phillips, et al.
Journal of the Neurological Sciences
|
July 28, 2024
Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets
Mathieu F Janssen, Sarah Dewilde, Gil I Wolfe, et al.
Multiple Sclerosis and Related Disorders
|
April 12, 2016
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial
Glenn Phillips, Shien Guo, Randall Bender, et al.
Expert Review of Cardiovascular Therapy
|
April 1, 2020
PROMIS® and Neuro-QoL<sup>TM</sup> measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome
Rina S Fox, John Devin Peipert, Montserrat Vera-Llonch, et al.
Multiple Sclerosis and Related Disorders
|
August 23, 2019
Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS)
Louis S Matza, Katie D Stewart, Glenn Phillips, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
February 17, 2017
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph Hb Benedict, John DeLuca, Glenn Phillips, et al.
Clinical Therapeutics
|
May 23, 2015
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
John O'Gorman, Heidy K Russell, Jie Li, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 24, 2017
The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms
Gisela Kobelt, Jennifer Eriksson, Glenn Phillips, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 26, 2025
Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample
Sarah Dewilde, Mathieu F Janssen, Glenn Phillips, et al.
Archives of Public Health = Archives Belges De Sante Publique
|
July 11, 2025
POPUP: an observational digital study reporting general population norms for the EQ-5D-5-L and HUI-3 in 8 countries
Sarah Dewilde, Nafthali Hananja Tollenaar, Glenn Phillips, et al.
Advances in Therapy
|
March 3, 2023
Association Between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities
Sarah Dewilde, Cynthia Z Qi, Glenn Phillips, et al.
Journal of the Neurological Sciences
|
July 28, 2024
Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets
Mathieu F Janssen, Sarah Dewilde, Gil I Wolfe, et al.
Multiple Sclerosis and Related Disorders
|
April 12, 2016
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial
Glenn Phillips, Shien Guo, Randall Bender, et al.
Expert Review of Cardiovascular Therapy
|
April 1, 2020
PROMIS® and Neuro-QoL<sup>TM</sup> measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome
Rina S Fox, John Devin Peipert, Montserrat Vera-Llonch, et al.
Multiple Sclerosis and Related Disorders
|
August 23, 2019
Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS)
Louis S Matza, Katie D Stewart, Glenn Phillips, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
February 17, 2017
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph Hb Benedict, John DeLuca, Glenn Phillips, et al.
Clinical Therapeutics
|
May 23, 2015
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
John O'Gorman, Heidy K Russell, Jie Li, et al.
Page
of 5